The global market for autologous matrix-induced chondrogenesis (AMIC) is expected to witness a high level of competition in the next few years, states a new market intelligence study by Transparency Market Research. The key players in the market are focusing on the expansion of the product portfolio, which is predicted to create growth opportunities for the market players in the next few years. In addition to this, the market players are focusing on the emerging economies, which is predicted to support the growth of the global autologous matrix-induced chondrogenesis market in the next few years. Some of the leading players operating in the autologous matrix-induced chondrogenesis market across the globe are Zimmer Biomet Holdings, Smith & Nephew Plc., and Geistlich Pharma AG.
According to a market research study published by Transparency Market Research, in 2015, the global market for autologous matrix-induced chondrogenesis was worth US$89.71 mn and is projected to reach a value of US$186.38 mn by the end of 2024. The market is anticipated to register a strong 8.60% CAGR between 2016 and 2024.
Request A Sample-
Rising Geriatric Population to Drive North America Market in Near Future
From a regional outlook, the global market for autologous matrix-induced chondrogenesis has been classified into the Middle East and Africa, North America, Latin America, Europe, and Asia Pacific. In the last few years, North America led the global market and is further projected to witness a high growth in the next few years.The rising prevalence of several joint and bone disorders, including rheumatoid and arthritis and the increasing geriatric population are some of the major factors that are projected to accelerate the growth of the North America market in the next few years. Furthermore, Europe is likely to witness a healthy growth in the next few years, thanks to the rising contribution from France and Germany. O